In January 2021, the groundbreaking ceremony for the pile foundation of the Sinocare iPOCT Industrial Park project was held at the project site. The project is a special iPOCT industrial park built by Sinocare with a RMB 1 billion investment. It is planned to be divided into three modules, namely iCARE production base, AGEscan production base and CGM production base. After the completion of the project, it will realize the large-scale production of iCARE and iCGMS, the new products developed by Sinocare worldwide, and provide more comprehensive solutions for the prevention and treatment of chronic diseases.

Since 2016, Sinocare has launched a global business layout, participated in the acquisition of Trividia Health Inc and PTS in the United States, and actively expanded the POCT testing business such as blood lipids and glycosylated hemoglobin. And through the collaborative innovation of research and development at home and abroad, and the integration of global marketing networks, it has entered the leading camp of global blood glucose meter companies.

The newly started Sinocare iPOCT Industrial Park project will be constructed in three phases, with an estimated construction period of five years. After completion, it is estimated that the annual output value will reach 3 billion, the tax contribution will increase by more than 200 million, and nearly 2,000 jobs will be created. While helping to enhance the comprehensive strength of Sinocare, it also injects impetus into the growth of the biomedicine and health industry chain in Changsha High-tech Zone.